FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239553742> ?p ?o ?g. }

• W4239553742 endingPage "S109.e33" @default.
• W4239553742 startingPage "S1" @default.
• W4239553742 abstract "Guideline SummaryChronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative. Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD) in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative." @default.
• W4239553742 created "2022-05-12" @default.
• W4239553742 creator A5000426865 @default.
• W4239553742 creator A5001454349 @default.
• W4239553742 creator A5002779647 @default.
• W4239553742 creator A5003774188 @default.
• W4239553742 creator A5005431603 @default.
• W4239553742 creator A5006844961 @default.
• W4239553742 creator A5007364645 @default.
• W4239553742 creator A5010931197 @default.
• W4239553742 creator A5013391830 @default.
• W4239553742 creator A5014777482 @default.
• W4239553742 creator A5016520112 @default.
• W4239553742 creator A5019229545 @default.
• W4239553742 creator A5019874488 @default.
• W4239553742 creator A5020751544 @default.
• W4239553742 creator A5023568881 @default.
• W4239553742 creator A5023816128 @default.
• W4239553742 creator A5024374488 @default.
• W4239553742 creator A5027199933 @default.
• W4239553742 creator A5027703697 @default.
• W4239553742 creator A5029045187 @default.
• W4239553742 creator A5029462708 @default.
• W4239553742 creator A5029976609 @default.
• W4239553742 creator A5033515344 @default.
• W4239553742 creator A5034035627 @default.
• W4239553742 creator A5035278353 @default.
• W4239553742 creator A5038012814 @default.
• W4239553742 creator A5040624287 @default.
• W4239553742 creator A5040632378 @default.
• W4239553742 creator A5042205831 @default.
• W4239553742 creator A5044920708 @default.
• W4239553742 creator A5045681348 @default.
• W4239553742 creator A5045922184 @default.
• W4239553742 creator A5049206580 @default.
• W4239553742 creator A5050638660 @default.
• W4239553742 creator A5054802858 @default.
• W4239553742 creator A5054996768 @default.
• W4239553742 creator A5058435122 @default.
• W4239553742 creator A5059503791 @default.
• W4239553742 creator A5061188268 @default.
• W4239553742 creator A5061233503 @default.
• W4239553742 creator A5063865051 @default.
• W4239553742 creator A5068512231 @default.
• W4239553742 creator A5069692585 @default.
• W4239553742 creator A5071794395 @default.
• W4239553742 creator A5073298637 @default.
• W4239553742 creator A5075227210 @default.
• W4239553742 creator A5076214797 @default.
• W4239553742 creator A5077104069 @default.
• W4239553742 creator A5078547794 @default.
• W4239553742 creator A5080074455 @default.
• W4239553742 creator A5080587763 @default.
• W4239553742 creator A5081212320 @default.
• W4239553742 creator A5083966674 @default.
• W4239553742 creator A5084897017 @default.
• W4239553742 creator A5086468988 @default.
• W4239553742 creator A5086841628 @default.
• W4239553742 creator A5087637496 @default.
• W4239553742 creator A5090442172 @default.
• W4239553742 creator A5091728341 @default.
• W4239553742 date "2019-07-01" @default.
• W4239553742 modified "2023-10-16" @default.
• W4239553742 title "Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia" @default.
• W4239553742 cites W1123078655 @default.
• W4239553742 cites W1485191699 @default.
• W4239553742 cites W1504954231 @default.
• W4239553742 cites W1505864279 @default.
• W4239553742 cites W1509738750 @default.
• W4239553742 cites W1514973749 @default.
• W4239553742 cites W1532938938 @default.
• W4239553742 cites W1552829599 @default.
• W4239553742 cites W1566511051 @default.
• W4239553742 cites W157533458 @default.
• W4239553742 cites W1575571504 @default.
• W4239553742 cites W1580483378 @default.
• W4239553742 cites W1606473227 @default.
• W4239553742 cites W1654518922 @default.
• W4239553742 cites W171552336 @default.
• W4239553742 cites W1752045965 @default.
• W4239553742 cites W1761241349 @default.
• W4239553742 cites W1812416290 @default.
• W4239553742 cites W1816562562 @default.
• W4239553742 cites W185013963 @default.
• W4239553742 cites W1860882400 @default.
• W4239553742 cites W1865517526 @default.
• W4239553742 cites W1871837494 @default.
• W4239553742 cites W1884641745 @default.
• W4239553742 cites W1893274044 @default.
• W4239553742 cites W1913626018 @default.
• W4239553742 cites W1923712277 @default.
• W4239553742 cites W1926783300 @default.
• W4239553742 cites W1939448573 @default.
• W4239553742 cites W1963607067 @default.
• W4239553742 cites W1964787081 @default.
• W4239553742 cites W1965576103 @default.
• W4239553742 cites W1965775731 @default.
• W4239553742 cites W1966751947 @default.

• next